Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Direct and immune mediated antibody targeting of ERBB receptors in a colorectal cancer cell-line panel.

Ashraf SQ, Nicholls AM, Wilding JL, Ntouroupi TG, Mortensen NJ, Bodmer WF.

Proc Natl Acad Sci U S A. 2012 Dec 18;109(51):21046-51. doi: 10.1073/pnas.1218750110. Epub 2012 Dec 3.

PMID:
23213241
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.

Juliachs M, Castillo-Ávila W, Vidal A, Piulats JM, Garcia Del Muro X, Condom E, Hernández-Losa J, Teixidó C, Pandiella A, Graupera M, Casanovas O, Germà JR, Villanueva A, Viñals F.

Int J Cancer. 2013 Jul;133(1):235-46. doi: 10.1002/ijc.28009. Epub 2013 Feb 12.

PMID:
23292912
[PubMed - indexed for MEDLINE]
3.

PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab.

Jhawer M, Goel S, Wilson AJ, Montagna C, Ling YH, Byun DS, Nasser S, Arango D, Shin J, Klampfer L, Augenlicht LH, Perez-Soler R, Mariadason JM.

Cancer Res. 2008 Mar 15;68(6):1953-61. doi: 10.1158/0008-5472.CAN-07-5659. Erratum in: Cancer Res. 2008 Aug 15;68(16):6859. Soler, Roman Perez [corrected to Perez-Soler, Roman]. Cancer Res. 2009 Dec 1;69(23):9156.

PMID:
18339877
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.

Yamazaki M, Yamashita Y, Kubo N, Yashiro M, Ohira M, Ako E, Tanaka H, Muguruma K, Sawada T, Hirakawa K.

Oncol Rep. 2012 Jul;28(1):49-54. doi: 10.3892/or.2012.1803. Epub 2012 May 4.

PMID:
22562413
[PubMed - indexed for MEDLINE]
5.

The ErbB/HER family of protein-tyrosine kinases and cancer.

Roskoski R Jr.

Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20. Review.

PMID:
24269963
[PubMed - indexed for MEDLINE]
6.

KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.

Messner I, Cadeddu G, Huckenbeck W, Knowles HJ, Gabbert HE, Baldus SE, Schaefer KL.

J Cancer Res Clin Oncol. 2013 Feb;139(2):201-9. doi: 10.1007/s00432-012-1319-7. Epub 2012 Sep 27.

PMID:
23015072
[PubMed - indexed for MEDLINE]
7.

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

PMID:
16818711
[PubMed - indexed for MEDLINE]
Free Article
8.

Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.

Friedländer E, Arndt-Jovin DJ, Nagy P, Jovin TM, Szöllosi J, Vereb G.

Cytometry A. 2005 Oct;67(2):161-71.

PMID:
16163699
[PubMed - indexed for MEDLINE]
Free Article
9.

Preclinical assessment of simultaneous targeting of epidermal growth factor receptor (ErbB1) and ErbB2 as a strategy for cholangiocarcinoma therapy.

Zhang Z, Oyesanya RA, Campbell DJ, Almenara JA, Dewitt JL, Sirica AE.

Hepatology. 2010 Sep;52(3):975-86. doi: 10.1002/hep.23773.

PMID:
20607690
[PubMed - indexed for MEDLINE]
11.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A.

J Clin Oncol. 2008 Dec 10;26(35):5705-12. doi: 10.1200/JCO.2008.18.0786. Epub 2008 Nov 10.

PMID:
19001320
[PubMed - indexed for MEDLINE]
Free Article
12.

Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.

Matar P, Rojo F, Cassia R, Moreno-Bueno G, Di Cosimo S, Tabernero J, Guzmán M, Rodriguez S, Arribas J, Palacios J, Baselga J.

Clin Cancer Res. 2004 Oct 1;10(19):6487-501.

PMID:
15475436
[PubMed - indexed for MEDLINE]
Free Article
13.

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

Tol J, Dijkstra JR, Klomp M, Teerenstra S, Dommerholt M, Vink-Börger ME, van Cleef PH, van Krieken JH, Punt CJ, Nagtegaal ID.

Eur J Cancer. 2010 Jul;46(11):1997-2009. doi: 10.1016/j.ejca.2010.03.036. Epub 2010 Apr 21.

PMID:
20413299
[PubMed - indexed for MEDLINE]
14.

Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.

Singla S, Pippin JA, Drebin JA.

Oncol Rep. 2012 Dec;28(6):2211-6. doi: 10.3892/or.2012.2053. Epub 2012 Sep 24.

PMID:
23007710
[PubMed - indexed for MEDLINE]
15.

Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.

Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, Gilmer TM.

Mol Cancer Ther. 2007 May;6(5):1629-40.

PMID:
17513611
[PubMed - indexed for MEDLINE]
Free Article
16.

Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.

Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.

J Natl Cancer Inst. 2011 Apr 20;103(8):674-88. doi: 10.1093/jnci/djr070. Epub 2011 Mar 11.

PMID:
21398618
[PubMed - indexed for MEDLINE]
Free Article
17.

Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.

Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A.

J Natl Cancer Inst. 2009 Oct 7;101(19):1308-24. doi: 10.1093/jnci/djp280. Epub 2009 Sep 8. Review.

PMID:
19738166
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

In pancreatic carcinoma, dual EGFR/HER2 targeting with cetuximab/trastuzumab is more effective than treatment with trastuzumab/erlotinib or lapatinib alone: implication of receptors' down-regulation and dimers' disruption.

Larbouret C, Gaborit N, Chardès T, Coelho M, Campigna E, Bascoul-Mollevi C, Mach JP, Azria D, Robert B, Pèlegrin A.

Neoplasia. 2012 Feb;14(2):121-30.

PMID:
22431920
[PubMed - indexed for MEDLINE]
Free PMC Article
19.
20.

Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells.

Köninki K, Barok M, Tanner M, Staff S, Pitkänen J, Hemmilä P, Ilvesaro J, Isola J.

Cancer Lett. 2010 Aug 28;294(2):211-9. doi: 10.1016/j.canlet.2010.02.002. Epub 2010 Mar 2.

PMID:
20193978
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk